Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial
Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; however, their safety and efficacy have not been compared. The objective of the POSEIDON Randomized Trial was to test whether allogeneic MSCs are as safe and effective as autologous MSCs in patients with left ventricular (LV) dysfunction due to ICM. In this early-stage study of patients, transendocardial injection of allogeneic and autologous MSCs without a placebo control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions. In aggregate, MSC injection favorably affected patient functional capacity, quality of life, and ventricular remodeling. View Article »
August 21, 2012 – Dr. Howard Walpole
Next Generation Cardiac Cell Therapy Demonstrates Great Potential in Heart Disease Clinical Trials
Cardiac cell therapy trials using adult bone marrow cells (BMC) were the subject of a large meta-analysis that showed that transplantation in patients with ischemic heart disease offers lasting improvements in key cardiac metrics compared with conventional therapy alone. View Article »
June 28, 2012 – TCTMD
Meta-analysis: Bone Marrow Cell Transplantation Effective for Ischemic Heart Disease
In a field characterized by mixed results and variable protocols, a large meta-analysis shows that transplantation of adult bone marrow cells (BMC) in patients with ischemic heart disease offers lasting improvements in key cardiac metrics compared with standard therapy alone. The study also suggests that the experimental treatment improves clinical outcomes. View Article »
April 02, 2012 – Medscape Education Cardiology
The Promise of Adipose-Derived Regenerative Cells
In March 2012, Leslie W. Miller, MD, FACC led discussions for CME credits with Deepak L. Bhatt, MD, MPH; Timothy Henry, MD; Emerson C. Perin, MD, PhD on The Promise of Adipose-Derived Regenerative Cells in Cardiovascular Medicine.Dr. Miller holds the Edward C. Wright Chair of Cardiovascular Medicine at University of South Florida (USF) and is the Director/ CEO of the USF Cardiovascular Clinical and Research Integrated Strategic Program, or CRISP. In addition, Dr. Miller is a member of the Okyanos Medical Advisory Council. Each of these leaders in cardiology provided insights and understandings as well as areas that need further exploration in the field of cardiac cell therapy. View Article »
Referring a Patient
As a referring physician, we will work with you on a case-by-case basis to determine if cardiac cell therapy is an approach that may help your patient. Post treatment, Okyanos Heart Institute will provide copies of all diagnostic and treatment records.
To support the critical research function of Okyanos, we seek your ongoing partnership with our on-line patient registry. The objective of the registry is to capture key longitudinal data (e.g., echocardiography, stress test) post-treatment. Your participation in the registry will assist in the further progress of cardiac cell therapy and without doubt improve the quality of life for future patients suffering with heart failure. With your permission, Okyanos will send you all registry related publications.